What is the Size of the Cell and Gene Therapy Market?
According to the latest report on the cell and gene therapy market from Kalorama Information, the global market for cell and gene therapy in 2020 is estimated to reach $3,866 millionAnd most of the market is for the treatment of cancer. Dermatological, Cardiovascular – Blood, Oncology, Ophthalmic, Musculoskeletal and other conditions. With the COVID-19 crisis, there are some efforts to adapt this promising technology to the treatment and prevention of the disease. But oncology still dominates.
This is an exciting and interesting time in the cell and gene therapy industry. The science is moving ahead as industry industrializes and standardizes the manufacturing and commercialization of products. Cell and gene therapy products are transforming the treatment of cancers and genetic diseases, as well as expanding into other areas of medicine including autoimmune diseases, cardiovascular diseases, musculoskeletal disease, dermatological diseases, and many others.
Who are the Leading Influencers in Cell and Gene Therapy?
The leading influencers in the market are those which have become first-to-market participants in the cell and gene therapy segment, have new developments which may disrupt current market conditions, and/or have an extensive pipeline sure to impact the market in the long-term forecast:
Advantagene
Advaxis
AlloSource
Alnylam Pharmaceuticals
Amgen
AnGes USA
Anterogen
Atara Therapeutics
Athersys
AveXis
BioCardia
BioMarin Pharmaceuticals
Bluebird bio
BrainStorm Cell Therapeutics
Caladrius Bioscience
Celyad
Cook MyoSite
Cytori Therapeutics
Dendreon
Ferring Pharmaceuticals
Fibrocell
Gamida Cell
GenSight Biologics
Genzyme
Gilead Sciences
Gradalis
Inovio Pharmaceuticals
Kiadis Pharma
Medeor Therapeutics
Medipost
Merck
Mesoblast
MolMed
Neurotech USA
Nightstar Therapeutics
Northwest Biotherapeutics
Novartis
NuVasive
Orchard Therapeutics
Organogenesis
Orthofix
Osiris Therapeutics (part of Smith & Nephew)
Pharmicell
Pluristem Therapeutics
Quark Pharmaceuticals
Renova Therapeutics
Sanofi Pasteur
SOTIO
Spark Therapeutics
Tessa Therapeutics
Tocagen
uniQure
VBL Therapeutics
ViroMed
Cell Therapies in Development by Type
Authoritative Information on Cell and Gene Therapy Markets
Cell Therapy and Gene Therapy Markets from Kalorama Information presents the market in segments that provide an overview of disease epidemiology, market estimates and forecasts, and competitive summary of leading providers:
Cell and Gene Therapy Market Summary by Product Segment, 2020-2030 ($ millions) (Dermatological, Cardiovascular – Blood, Oncology, Ophthalmic, Musculoskeletal, Other conditions, Total Market)
Cell and Gene Therapy Market Summary by Method, 2020-2030 ($ millions) (Cell Therapy, Gene Therapy, Total Market)
Cell and Gene Therapy Market Summary by Geographical Region, 2020-2030 ($ millions) (United States, Europe/European Union, Other Countries, Global Market)
Cell and Gene Therapy Market Summary for United States by Product Segment, 2020-2030 ($ millions) (Dermatological, Cardiovascular – Blood, Oncology, Ophthalmic, Musculoskeletal, Other conditions, Total)
U.S. Cell and Gene Therapy Market, Distribution by Product Segment (Dermatological, Cardiovascular-blood, Oncology, Ophthalmic, Musculoskeletal, Other conditions), 2020 (%)
Europe Cell and Gene Therapy Market, Distribution by Product Segment (Dermatological, Cardiovascular-blood, Oncology, Ophthalmic, Musculoskeletal, Other conditions), 2020 (%)
Other Countries Cell and Gene Therapy Market, Distribution by Product Segment (Dermatological, Cardiovascular-blood, Oncology, Ophthalmic, Musculoskeletal, Other conditions), 2020 (%)
Estimated Cell and Gene Therapy Sales by Leading Competitor, 2019 Sales ($ millions)
The report examines developments in cell and gene therapy markets by condition/disorder, including principal products, trends in research and development, market breakdown of cell and gene therapies, regional market summary, and competitor summary. The following conditions/disorders are covered:
Dermatology, including:
Dermatology Cell and Gene Therapy Markets by Product Type, Estimated 2020 and Projected 2025 and 2030 ($ millions) (Stem cells, Skin cells)
Dermatology Cell and Gene Therapy Market by General Indication, Estimated 2020, Projected 2025 and 2030 ($ millions) (Wound healing/treatment, Other indications [wrinkles, scar treatment])
Dermatology Cell and Gene Therapy Market by Country/Region, Estimated 2020, Projected 2025 and 2030 ($ millions) (United States, Europe/European Union, S. Korea, Other countries)
Dermatology Cell and Gene Therapy Competitor Market Share, Reported and Estimated 2019 ($ millions)
Cardiovascular and Blood Disorders, including:
Cardiovascular and Blood Disorders Cell and Gene Therapy Markets by Product Type, Estimated 2020 and Projected 2025 and 2030 ($ millions) (Stem cells, Gene therapy, Other cell therapies; Stromal cells)
Cardiovascular and Blood Disorders Cell and Gene Therapy Market by General Indication, Estimated 2020, Projected 2025 and 2030 ($ millions) (Cardiac disorders, Vascular disorders, Blood disorders, Hypercholesterolemia)
Cardiovascular and Blood Disorders Cell and Gene Therapy Market Summary by Geographic Region, Estimated 2020 and Projected 2025, 2030 ($ millions) (United States, Europe, S. Korea, Japan, ROW)
Oncology, including:
Oncology Cell and Gene Therapy Markets by Product Type, Estimated 2020 and Projected 2025 and 2030 ($ millions) (CAR-T, Cell immunotherapy, Gene therapy, Other cell therapy)
Oncology Cell and Gene Therapy Market by General Indication, Estimated 2020, Projected 2025 and 2030 ($ millions) (Blood cancers, Prostate cancer, Melanoma, Other cancers)
Oncology Cell and Gene Therapy Market Summary by Geographic Region, Estimated 2020 and Projected 2025, 2030 ($ millions) (United States, Europe, ROW)
Oncology Cell and Gene Therapy Competitor Market Share, Reported and Estimated 2019 ($ millions)
Ophthalmic Conditions, including:
Ophthalmology Cell and Gene Therapy Markets by Product Type, Estimated 2020 and Projected 2025 and 2030 ($ millions) (Stem cells, Gene therapy, Other cell therapy)
Ophthalmology Cell and Gene Therapy Market Summary by Geographic Region, Estimated 2020 and Projected 2025, 2030 ($ millions) (United States, Europe, Other countries)
Musculoskeletal Conditions and Disorders, including:
Musculoskeletal Cell Therapy Market, Estimated 2020 and Projected 2025 and 2030 ($ millions)
Musculoskeletal Cell and Gene Therapy Market by General Indication, Estimated 2020, Projected 2025 and 2030 ($ millions) (Cartilage Defect/Damage Repair, Bone Defect/Damage Repair, Others [tendon damage, osteoarthritis])
Musculoskeletal Cell and Gene Therapy Market by Country/Region, Estimated 2020, Projected 2025 and 2030 ($ millions) (United States, Europe/European Union, S. Korea, Other countries)
Other Conditions Cell and Gene Therapy Markets by Product Type, Estimated 2020 and Projected 2025 and 2030 ($ millions) (Cell therapy, Gene therapy, Gene-modified cell therapy)
Other Conditions Cell and Gene Therapy Market by Country/Region, Estimated 2020, Projected 2025 and 2030 ($ millions) (United States, Europe/European Union, S. Korea, Other countries)
Cell Therapy and Gene Therapy Markets also includes several discussions on cell and gene therapies in development and the impact these are expected to have on the market. Throughout the report, several market indicators, trends, and barriers are discussed.
CAGRS of Various Cell and Gene Therapy Segments
(more information with report purchase)
The report comments on the current COVID-19 cell and gene therapy pipeline. There are a number of companies that are responding to the call to develop a therapeutic or vaccine for the coronavirus, including:
Vitro Biopharma
Celularity and Sorrento Therapeutics
CanSino Biologics
Mesoblast
Acturus Therapeutics
Entos Pharmaceuticals
Zydus Cadila
AlloVir and Baylor College of Medicine
Athersys
Exothera
Sirnaomics
Mesoblast
Table of Contents
Chapter 1: Executive Summary
Overview
Scope and Methodology
Market Overview and Potential
Figure 1-1: Global Cell and Gene Therapy Market CAGR by Product Segment, 2019-2030 (Dermatological, Cardiovascular-Blood, Oncology, Ophthalmic, Musculoskeletal, Other Conditions)
Coronavirus Cell and Gene Therapy Pipeline
Chapter 2: Introduction to Cell and Gene Therapy
Introduction
Cell Therapy
Table 2-1: Adult vs. Embryonic Stem Cells
Gene Therapy
Table 2-2: Somatic vs. Germ Line Gene Therapy
Viral Vector System and New Developments
Table 2-3: Examples of Viruses in Gene Therapy
Figure 2-1: Gene Therapy Vector Type Distribution, Commercialized (current and former) Products (%) (Retrovirus and Gamma-Retrovirus, Lentiviral, Non-viral, Herpes Simplex Virus, Adeno and Adeno-associated Virus)
Non-viral Systems for Transporting Genes
Gene Editing
Cell and Gene Therapy: Characteristics
Table 2-4: Cell Therapy vs. Gene Therapy
Table 2-5: Autologous vs. Allogeneic Cell and Gene Therapies, Commercialized Products
Figure 2-2: Cell and Gene Therapy, Autologous and Allogeneic Distribution for Commercialized Products (%)
Figure 2-3: Cell and Gene Therapy (combined autologous and allogeneic), Route of Administration Distribution for Commercialized Products (%) (Topical, Implant, Intravenous, Injection)
Staffing
Manufacturing Process for CAR-T
Leukapheresis
Activation
Transduction
Expansion
Advancements and Barriers in Manufacturing Processes
Table 2-6: Manufacturing Process Time for Select Autologous Cell and Gene Therapies (current and discontinued therapies)
Figure 2-4: Manufacturing Process Time for Select Autologous Cell and Gene Therapies (current and discontinued therapies)
Cost
Reimbursement
Logistics
Mergers and Acquisitions
Table 2-7: Select Company Mergers and Acquisitions in the Cell and Gene Therapy Market
Regulatory Developments
Fast Track
Orphan Drug
Breakthrough Therapy
Accelerated Approval
Priority Review
Table 2-8: Regulatory Actions and Guidelines for Cell and Gene Therapy by Select Country
Individualized Gene Therapy Approval Process
Development and Pipeline Overview
Development Progress
Figure 2-5: Global Cell and Gene Therapy Development Progress (phase I through phase III)
Figure 2-6: Global Cell and Gene Therapy Development Progress by Phase (%)
Development by Condition/Disorder
Figure 2-7: Global Development of Cell and Gene Therapies by Target (%) (Oncology; Genetic disorders; Hematology; Immunology; Endocrine, metabolic; Cardiovascular; Musculoskeletal disorders; Infectious disease; Ophthalmology; Gastroenterology; Respiratory; Dermatology; Neurology; Other disorders)
Phase III Development
Table 2-9: Phase III Development æ Cell and Gene Therapies, Select Projects
Figure 2-8: Cell and Gene Therapy: Top 30 Developers (Phase I through Submission)
End User
Hospitals
Research Institutes
Wound Care Centers
Cancer Centers
Chapter 3: Cell and Gene Therapy Markets in Dermatology
Overview
Table 3-1: Wound Prevalence by Type
Market Outlook
Figure 3-1: Cell and Gene Therapy Markets in Dermatology, 2019-2030 ($ millions)
Principal Products
Apligraf
CureSkin
Dermagraft
Epicel
Gintuit
Grafix
Holoderm
Kaloderm
KeraHeal/KeraHeal-Allo
LaViv
Orcel
Quencell
RECELL
Rosmir
Stravix
TransCyte
Table 3-2: Cell and Gene Therapy in Dermatological Diseases and Disorders
Figure 3-2: Dermatology Cell and Gene Therapy Approvals by Year or Year Range, through 2019
Trends in Research and Development
Table 3-3: Dermatology Cell and Gene Therapies in Development by Phase (%), March 2020 Data
Table 3-4: Dermatology Cell and Gene Therapies in Development by Method (%), March 2020 Data (Cell, Gene, Gene-modified Cell)
Market Breakdown of Cell and Gene Therapies
Table 3-5: Dermatology Cell and Gene Therapy Markets by Product Type, Estimated 2020 and Projected 2025 and 2030 ($ millions) (Stem cells, Skin cells)
Figure 3-3: Dermatology Cell and Gene Therapy Markets by Product Type, 2017 – 2030 ($ millions) (Stem cells, Skin cells)
Figure 3-4: Dermatology Cell and Gene Therapy Market Distribution by Product Type, 2020 (%) (Stem cells, Skin cells)
Dermatology Cell and Gene Therapy Market by Indication
Table 3-6: Dermatology Cell and Gene Therapy Market by General Indication, Estimated 2020, Projected 2025 and 2030 ($ millions) (Wound healing/treatment, Other indications [wrinkles, scar treatment])
Figure 3-5: Dermatology Cell and Gene Therapy Market by General Indication, 2017 – 2030 ($ millions) (Wound healing/treatment, Others [wrinkles, scar treatment])
Regional Market Summary
Figure 3-6: Dermatology Cell and Gene Therapy Approvals by Country/Region, through 2019 (United States, Europe/European Union, S. Korea, Canada, Australia/New Zealand, Japan, China, Other countries)
Table 3-7: Dermatology Cell and Gene Therapy Market by Country/Region, Estimated 2020, Projected 2025 and 2030 ($ millions) (United States, Europe/European Union, S. Korea, Other countries)
Figure: 3-7: Dermatology Cell and Gene Therapy Market Summary by Geographic Region, Estimated 2020 and Projected 2025, 2030 ($ millions) (United States, Europe, S. Korea, Other countries [Australia, Canada, China, Singapore, etc.])
Competitor Summary
Table 3-8: Dermatology Cell and Gene Therapy Competitor Market Share, Reported and Estimated 2019 ($ millions)
Chapter 4: Cell and Gene Therapy Markets in Cardiovascular and Blood Disorders
Overview
Cardiovascular Disease
Selected Blood Disorders
Market Outlook
Figure 4-1: Cell and Gene Therapy Markets in Cardiovascular and Blood Disorders, 2019-2030 ($ millions)
Principal Products
Collategene
Hearticellgram
HeartSheet
Neovasculgen
Stempeucel
Zynteglo
Cord Blood Products
Table 4-1: Cell and Gene Therapy in Cardiovascular and Blood Disorders
Figure 4-2: Cardiovascular and Blood Disorders Cell and Gene Therapy Approvals by Year, through 2019
Trends in Research and Development
Table 4-2: Cardiovascular and Blood Disorders Cell and Gene Therapies in Development by Phase (%), March 2020 Data
Table 4-3: Cardiovascular and Blood Disorders Cell and Gene Therapies in Development by Method (%), March 2020 Data (Cell, Gene, Gene-modified Cell)
Phase III Development
Table 4-4: Select Cardiovascular and Blood Disorder Phase III Cell and Gene Therapy Developments, through March 2020
Orphan Drug, Fast Track, Breakthrough Designations
Table 4-5: Orphan Drug, Fast Track and Breakthrough Designations for Cardiovascular and Blood Disorder Cell and Gene Therapies in Development (Phase I through III), through March 2020
Market Breakdown of Cell and Gene Therapies
Table 4-6: Cardiovascular and Blood Disorders Cell and Gene Therapy Markets by Product Type, Estimated 2020 and Projected 2025 and 2030 ($ millions) (Stem cells, Gene therapy, Other cell therapies; Stromal cells)
Figure 4-3: Cardiovascular and Blood Disorders Cell and Gene Therapy Markets by Product Type, 2017 – 2030 ($ millions) (Stem cells, Other cell therapy, Gene therapy, Stromal cells)
Figure 4-4: Cardiovascular and Blood Disorders Cell and Gene Therapy Market Distribution by Product Type, 2020 (%) (Gene therapy, Stem cells, Other cell therapy, Stromal cells)
Cardiovascular and Blood Disorders Cell and Gene Therapy Market by Indication
Table 4-7: Cardiovascular and Blood Disorders Cell and Gene Therapy Market by General Indication, Estimated 2020, Projected 2025 and 2030 ($ millions) (Cardiac disorders, Vascular disorders, Blood disorders, Hypercholesterolemia)
Figure 4-5: Cardiovascular and Blood Disorders Cell and Gene Therapy Market by General Indication, 2017 – 2030 ($ millions) (Cardiac disorders, Vascular disorders, Blood disorders, Hypercholesterolemia)
Figure 4-6: Cardiovascular and Blood Disorders Cell and Gene Therapy Market by General Indication (wound healing/treatment vs. other indications), Estimated 2020 (%) (Blood disorders, Cardiac disorders, Vascular disorders, Hypercholesterolemia)
Regional Market Summary
Figure 4-7: Cardiovascular and Blood Disorders Cell and Gene Therapy Approvals by Country/Region, through 2019 (United States, Europe/European Union, S. Korea, India, Japan, Other countries)
Table 4-8: Cardiovascular and Blood Disorders Cell and Gene Therapy Market by Country/Region, Estimated 2020, Projected 2025 and 2030 ($ millions) (United States, Europe/European Union, Japan, Other countries)
Figure 4-8: Cardiovascular and Blood Disorders Cell and Gene Therapy Market Summary by Geographic Region, Estimated 2020 and Projected 2025, 2030 ($ millions) (United States, Europe, S. Korea, Japan, ROW)
Competitor Summary
Chapter 5: Cell and Gene Therapy Markets in Oncology
Overview
Biochemistry of Cancer Cells
Causes of Cancer Growth
Environmental Factors, DNA, RNA
Table 5-1: Virus Association with Human Cancer
Cellular Oncogenes
Tumor Suppressor Genes
CAR-T Therapies
Global Cancer Burden
Figure 5-1: Global Cancer Incidence Trends, 2010-2040
Figure 5-2: Incidence of Cancer by Type, 2018 (Lung, Breast, Colorectum, Prostate, Stomach, Liver, Oesophagus, Cervix uteri, Thyroid, Bladder)
Figure 5-3: Distribution of Cancer Incidence by Type, 2018 (Lung, Breast, Colorectum, Prostate, Stomach, Liver, Oesophagus, Cervix uteri, Thyroid, Bladder, Others)
Market Outlook
Figure 5-4: Cell and Gene Therapy Markets in Oncology, 2019-2030 ($ millions)
Principal Products
APCeden
CreaVax-RCC
Gendicine
Imlygic
Immuncell-LC
Kymriah
Provenge
Yescarta
Zalmoxis
Table 5-2: Cell and Gene Therapy in Oncology
Figure 5-5: Oncology Cell and Gene Therapy Approvals by Year, through 2019
Trends in Research and Development
Table 5-3: Oncology Cell and Gene Therapies in Development by Phase (%), March 2020 Data
Table 5-4: Oncology Cell and Gene Therapies in Development by Method (%), March 2020 Data (Cell, Gene, Gene-modified Cell)
Figure 5-6: Oncology Cell and Gene Therapy Development by Cancer Type, March 2020 Data (Phase I through Phase III) (Anal, Bladder, Brain, Breast, Cancer [unspecified], Cervical, Colorectal, Head & Neck, Hematologic [leukemia and general], Liver, Lung, Lymphoma, Melanoma, Multiple Myeloma, Other, Ovarian, Pancreatic, Prostate, Renal, Solid Tumors)
Phase III Development
Table 5-5: Select Oncology Phase III Cell and Gene Therapy Developments, through March 2020
Orphan Drug, Fast Track, Breakthrough Designations
Table 5-6: Orphan Drug, Fast Track and Breakthrough Designations for Oncology Cell and Gene Therapies in Development (Phase I through III), FDA Reported, through March 2020
Market Breakdown of Cell and Gene Therapies
Table 5-7: Oncology Cell and Gene Therapy Markets by Product Type, Estimated 2020 and Projected 2025 and 2030 ($ millions) (CAR-T, Cell immunotherapy, Gene therapy, Other cell therapy)
Figure 5-7: Cell and Gene Therapy Markets by Product Type, 2017 – 2030 ($ millions) (CAR-T, Cell immunotherapy, Gene therapy, Other cell therapy)
Figure 5-8: Oncology Cell and Gene Therapy Market Distribution by Product Type, 2020 (%) (CAR-T, Cell immunotherapy, Gene therapy, Other cell therapy)
Oncology Cell and Gene Therapy Market by Cancer Type
Table 5-8: Oncology Cell and Gene Therapy Market by General Indication, Estimated 2020, Projected 2025 and 2030 ($ millions) (Blood cancers, Prostate cancer, Melanoma, Other cancers)
Figure 5-9: Oncology Cell and Gene Therapy Market by General Indication, 2017 – 2030 ($ millions) (Blood cancers [lymphoma, leukemia], Prostate cancer, Melanoma, Other cancer)
Figure 5-10: Oncology Cell and Gene Therapy Market by General Indication (Blood cancers, Prostate cancer, Melanoma, Other cancers), Estimated 2020 (%)
Regional Market Summary
Figure 5-11: Oncology Cell and Gene Therapy Approvals by Country/Region, through 2019 (United States, Europe/European Union, S. Korea, Other countries)
Table 5-9: Oncology Cell and Gene Therapy Market by Country/Region, Estimated 2020, Projected 2025 and 2030 ($ millions) (United States, Europe/European Union, Other countries)
Figure: 5-12: Oncology Cell and Gene Therapy Market Summary by Geographic Region, Estimated 2020 and Projected 2025, 2030 ($ millions) (United States, Europe, ROW)
Competitor Summary
Table 5-10: Oncology Cell and Gene Therapy Competitor Market Share, Reported and Estimated 2019 ($ millions)
Chapter 6: Cell and Gene Therapy Markets in Ophthalmic Conditions
Overview
Market Outlook
Figure 6-1: Cell and Gene Therapy Markets in Ophthalmic Conditions, 2019-2030 ($ millions)
Principal Products
Holoclar
Luxturna
Table 6-1: Cell and Gene Therapy in Ophthalmic Conditions
Trends in Research and Development
Table 6-2: Ophthalmology Cell and Gene Therapies in Development by Phase (%), March 2020 Data
Table 6-3: Ophthalmology Cell and Gene Therapies in Development by Method (%), March 2020 Data (Cell, Gene, Gene-modified cell)
Phase III Development
Table 6-4: Select Ophthalmology Phase III Cell and Gene Therapy Developments, through March 2020
Orphan Drug, Fast Track, Breakthrough Designations
Table 6-5: Orphan Drug, Fast Track and Breakthrough Designations for Ophthalmology Cell and Gene Therapies in Development (Phase I through III), FDA Reported, through March 2020
Market Breakdown of Cell and Gene Therapies
Table 6-6: Ophthalmology Cell and Gene Therapy Markets by Product Type, Estimated 2020 and Projected 2025 and 2030 ($ millions) (Stem cells, Gene therapy, Other cell therapy)
Figure 6-2: Ophthalmology Cell and Gene Therapy Markets by Product Type, 2017 – 2030 ($ millions) (Stem cells, Gene therapy, Other cell therapy)
Figure 6-3: Ophthalmology Cell and Gene Therapy Market Distribution by Product Type, 2020 (%) (Stem cells, Gene therapy, Other cell therapy)
Regional Market Summary
Table 6-7: Ophthalmology Cell and Gene Therapy Market by Country/Region, Estimated 2020, Projected 2025 and 2030 ($ millions) (United States, Europe/European Union, Other countries)
Figure: 6-4: Ophthalmology Cell and Gene Therapy Market Summary by Geographic Region, Estimated 2020 and Projected 2025, 2030 ($ millions) (United States, Europe, Other countries)
Competitor Summary
Chapter 7: Cell and Gene Therapy Markets in Musculoskeletal Conditions and Disorders
Overview
Market Outlook
Figure 7-1: Cell and Gene Therapy Markets in Musculoskeletal Conditions and Disorders, 2019-2030 ($ millions)
Principal Products
AlloStem
BIO4
Carticel
Cartiform
CartiLife
Cartistem
ChondroCelect
Chondron
JACC
MACI
Ortho-ACI and Ortho-ATI
Ossron
Osteocel and Osteoplus
Spherox
Trinity Elite and Trinity Evolution
Table 7-1: Cell and Gene Therapy in Musculoskeletal Diseases and Disorders
Figure 7-2: Musculoskeletal Cell Therapy Approvals by Year or Year Range, through 2019
Trends in Research and Development
Table 7-2: Musculoskeletal Cell and Gene Therapies in Development by Phase (%), March 2020 Data
Table 7-3: Musculoskeletal Cell and Gene Therapies in Development by Method (%), March 2020 Data (Cell, Gene, Gene-modified cell)
Market Breakdown of Cell Therapies
Table 7-4: Musculoskeletal Cell Therapy Market, Estimated 2020 and Projected 2025 and 2030 ($ millions)
Table 7-5: Musculoskeletal Cell and Gene Therapy Market by General Indication, Estimated 2020, Projected 2025 and 2030 ($ millions) (Cartilage Defect/Damage Repair, Bone Defect/Damage Repair, Others [tendon damage, osteoarthritis])
Figure 7-4: Musculoskeletal Cell and Gene Therapy Market by General Indication, 2017 – 2030 ($ millions) (Cartilage Defect/Damage Repair, Bone Defect/Damage Repair, Others [tendon damage, osteoarthritis])
Figure 7-5: Musculoskeletal Cell Therapy Market by General Indication (Cartilage treatment, Bone treatment and Other indications), Estimated 2020 (%) (Cartilage Defect/Damage Repair, Bone Defect/Damage Repair, Others [tendon damage, osteoarthritis])
Regional Market Summary
Figure 7-6: Musculoskeletal Cell Therapy Approvals by Country/Region (%), through 2019 (United States, Europe/European Union, Other countries)
Table 7-6: Musculoskeletal Cell and Gene Therapy Market by Country/Region, Estimated 2020, Projected 2025 and 2030 ($ millions) (United States, Europe/European Union, S. Korea, Other countries)
Figure: 7-7: Musculoskeletal Cell and Gene Therapy Market Summary by Geographic Region, Estimated 2020 and Projected 2025, 2030 ($ millions) (United States, Europe, S. Korea, Other countries [Australia, Japan, Canada, India])
Chapter 8: Cell and Gene Therapy Markets in Other Conditions
Overview
Market Outlook
Figure 8-1: Cell and Gene Therapy Markets in Other Conditions, 2019-2030 ($ millions)
Principal Products
Alofisel
Cupistem
Givlaari
Glybera
NeuroNata-R
Onpattro
Stemirac
Strimvelis
Temcell/Prochymal
Zolgensma
Table 8-1: Cell and Gene Therapy in Other Diseases and Disorders
Trends in Research and Development
Table 8-2: Other Conditions and Disorders: Cell and Gene Therapies in Development by Segment and Phase (%), March 2020 Data (ALS, Alzheimer’s disease, Autoimmune diseases, Diabetes, Fabry’s disease, HIV, Immune/transplant, Infectious diseases (excluding HIV), Liver disease, Multiple sclerosis, Muscular dystrophy, Other conditions (not categorized), Other genetic (not listed), Other neurological (not listed), Parkinson’s disease, PKU, Pompe disease, Renal disease, Respiratory diseases, Spinal cord injury, Traumatic brain injury, Urological disorders)
Market Breakdown of Cell and Gene Therapies
Table 8-3: Other Conditions Cell and Gene Therapy Markets by Product Type, Estimated 2020 and Projected 2025 and 2030 ($ millions) (Cell therapy, Gene therapy, Gene-modified cell therapy)
Figure 8-2: Other Conditions Cell and Gene Therapy Markets by Product Type, 2017 – 2030 ($ millions) (Cell therapy, Gene therapy, Gene-modified cell therapy)
Figure 8-3: Other Conditions Cell and Gene Therapy Market Distribution by Product Type, 2020 (%) (Cell therapy, Gene therapy, Gene-modified cell therapy)
Regional Market Summary
Table 8-4: Other Conditions Cell and Gene Therapy Market by Country/Region, Estimated 2020, Projected 2025 and 2030 ($ millions) (United States, Europe/European Union, S. Korea, Other countries)
Figure 8-4: Other Conditions Cell and Gene Therapy Market Summary by Geographic Region, Estimated 2020 and Projected 2025, 2030 ($ millions) (United States, Europe, S. Korea, Other countries)
Competitor Summary
Chapter 9: Cell and Gene Therapy Market Review
Market Influences
Global Demographics
Table 9-1: Global Population, through 2050 (population in millions)
Figure 9-1: Global Population Trends, Total Population vs. Age 65+ Population, 2000-2050
Cost Containment
Table 9-2: Cost Comparisons for Commercialized Cell and Gene Therapies
Global Market Summary
Table 9-3: Cell and Gene Therapy Market Summary by Product Segment, 2020-2030 ($ millions) (Dermatological, Cardiovascular – Blood, Oncology, Ophthalmic, Musculoskeletal, Other conditions, Total Market)
Cell vs. Gene Therapy Markets
Table 9-4: Cell and Gene Therapy Market Summary by Method, 2020-2030 ($ millions) (Cell Therapy, Gene Therapy, Total Market)
Regional Market Overview
Table 9-5: Cell and Gene Therapy Market Summary by Geographical Region, 2020-2030 ($ millions) (United States, Europe/European Union, Other Countries, Global Market)
United States
Table 9-6: Cell and Gene Therapy Market Summary for United States by Product Segment, 2020-2030 ($ millions) (Dermatological, Cardiovascular – Blood, Oncology, Ophthalmic, Musculoskeletal, Other conditions, Total)
Figure 9-2: U.S. Cell and Gene Therapy Market, Distribution by Product Segment (Dermatological, Cardiovascular-blood, Oncology, Ophthalmic, Musculoskeletal, Other conditions), 2020 (%)
Table 9-7: Major Cell and Gene Therapy Product Approvals, FDA
Europe/European Union
Table 9-8: Cell and Gene Therapy Market Summary for Europe/European Union by Product Segment, 2020-2030 ($ millions) (Dermatological, Cardiovascular – Blood, Oncology, Ophthalmic, Musculoskeletal, Other conditions, Total)
Figure 9-3: Europe Cell and Gene Therapy Market, Distribution by Product Segment (Dermatological, Cardiovascular-blood, Oncology, Ophthalmic, Musculoskeletal, Other conditions), 2020 (%)
Table 9-9: Major Cell and Gene Therapy Approvals by EMA
Other Countries
Table 9-10: Cell and Gene Therapy Market Summary for Other Countries by Product Segment, 2020-2030 ($ millions) (Dermatological, Cardiovascular – Blood, Oncology, Ophthalmic, Musculoskeletal, Other conditions, Total)
Figure 9-4: Other Countries Cell and Gene Therapy Market, Distribution by Product Segment (Dermatological, Cardiovascular-blood, Oncology, Ophthalmic, Musculoskeletal, Other conditions), 2020 (%)
Table 9-11: Select Major Cell and Gene Therapy Approvals by Various Regulatory Authorities
Competitor Ranking in Cell and Gene Therapy Markets
Table 9-12: Estimated Cell and Gene Therapy Sales by Leading Competitor, 2019 Sales ($ millions)
Chapter 10: Market Participants
Leading Influencers
Advantagene, Inc.
